{"id":944,"date":"2024-03-18T18:08:54","date_gmt":"2024-03-18T21:08:54","guid":{"rendered":"https:\/\/sfsafetyconsulting.com.br\/?p=944"},"modified":"2024-03-20T17:08:01","modified_gmt":"2024-03-20T20:08:01","slug":"relatorio-de-seguranca-de-cosmeticos-e-obrigatorio-na-europa-nos-estados-unidos-mocra-e-ate-na-china","status":"publish","type":"post","link":"https:\/\/sfsafetyconsulting.com.br\/en\/news\/cosmetics-safety-report-is-mandatory-in-europe-in-the-united-states-mocra-and-even-in-china\/","title":{"rendered":"Cosmetic Safety Report is Mandatory in Europe, the United States (MoCRA), and even in China"},"content":{"rendered":"

\"Cosmetics<\/p>\n

A report that includes a safety assessment cannot be confused with a clinical study of compatibility, or phototoxicity, or sensitization\/allergenicity.<\/p>\n

The dossier also includes other analyzes and at the end brings the verdict on the safety of the product according to its mode of use and exposure time.<\/p>\n

A single clinical study cannot be used to "topping up", <\/u><\/strong>or "declare"<\/u><\/strong> that the cosmetic product is safe to be placed on the market.<\/p>\n

The clinical study can take part<\/u><\/strong> of the safety dossier, where the absence or presence of adverse effects on humans is observed. This result is analyzed by a certified professional<\/strong> which, yes, the forehead<\/strong> that the product is safe (or not) for use as a cosmetic product.<\/p>\n

The Cosmetics Regulatory Modernization Act of 2022 (MoCRA) is the most significant expansion of the Food & Drug Administration's (FDA's) authority to regulate cosmetics in the United States since the Federal Food, Drug, and Cosmetic (FD&C) Act was passed. in 1938s.<\/p>\n

Companies and individuals that manufacture or sell cosmetics have a responsibility to ensure the safety of their products.<\/p>\n

Neither the law nor FDA regulations require specific testing to demonstrate the safety of individual products or ingredients, but the responsible person is required to have sufficient data to ensure and maintain records that support adequate proof of the safety of their cosmetic products.<\/p>\n

Manufacturers can use relevant toxicology data that is already available to support the safety of their products.<\/p>\n

It is important that all data used to support the safety dossier are derived from scientifically robust methods, both non-clinical and clinical methods.<\/p>\n

The presentation of a safety report, prepared by a certified safety assessor, is mandatory in Europe and must be part of the product information file (Product Information File \u2013 PIF).<\/p>\n

The safety report for a cosmetic product (Cosmetic Product Safety Report \u2013 CPSR) must contain, at a minimum:<\/p>\n